Healthcare Equipment and Supplies
Company Overview of Oncimmune Limited
Oncimmune Limited develops and commercializes products for the detection of cancerous tumors. It offers EarlyCDT that detects and measures auto antibodies that immune system produces in response to antigens generated by cancerous tumors; and EarlyCDT-Lung, a blood test that detects the body's immune response in the form of antibodies to certain proteins produced by cancer cells. The company was incorporated in 2002 and is based in Nottingham, the United Kingdom.
Clinical Sciences Building
Nottingham City Hospital
Nottingham, NG5 1PB
Founded in 2002
Key Executives for Oncimmune Limited
Executive Chief Executive Officer and Director
Chief Financial Officer and Director
Chief Operational Scientist
Compensation as of Fiscal Year 2015.
Oncimmune Limited Key Developments
Oncimmune Announces the Appointment of James Jett as Chief Medical Officer
Nov 19 15
Oncimmune announced the appointment of Dr. James Jett, as Chief Medical Officer. Dr. Jett is currently Professor of Medicine in the Division of Oncology at National Jewish Health in the USA, where his research includes conducting clinical trials related to the screening and early detection of lung cancer. Prior to joining National Jewish Health in 2010, he held appointments as Professor of Medicine at Mayo Medical School and the University of Pittsburgh. Dr. Jett joins Oncimmune on January 1, 2016 and will be based in the US. He will support all aspects of the Company's research and development as Oncimmune continues the further commercialisation of EarlyCDT®-Lung on a global basis and the launch of new EarlyCDT® cancer tests.
Oncimmune Announces Appointment of Meinhard Schmidt as Non-Executive Chairman
Sep 14 15
Oncimmune announced the appointment of Meinhard Schmidt as Non-Executive Chairman. Meinhard has more than 25 years international experience as an entrepreneur and senior executive in the diagnostics and medical devices industries. Between 1998 and 2008 he was at Roche Diagnostics where he held various global senior leadership roles and was global Senior VP at Lab Diagnostics, which achieved the leading global position in the laboratory industry. Meinhard has strong board level experience and has worked across M&A, global operations, sales and marketing, program and innovation management and has held executive management positions in Germany, The Netherlands, USA, Canada, Sweden, UK and Switzerland. He currently serves as Board Director at Sphere Medical PLC, valuationLAB AG, CeQur AG and as Chairman at Promimic AB.
Glycotest, Inc. Enters into a Research Collaboration with Oncimmune Ltd
Oct 3 14
NetScientific announced its portfolio company Glycotest, Inc. has entered into a research collaboration with Oncimmune Ltd. to explore the combined application of their proprietary tests in the early detection of liver cancer. Oncimmune has previously commercialised its proprietary autoantibody assay technology for the early detection of lung cancer with its EarlyCDT-Lung test and is now expanding this technology to the detection of liver cancer as well as other solid tumour cancers. Glycotest is developing proprietary glycoprotein biomarkers and assay technology for the surveillance of serious liver diseases, including liver cancer. Under the terms of the agreement, Glycotest and Oncimmune will conduct a joint clinical evaluation of their combined tests, which could then be co-developed as agreed by the collaborators.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries